ENCINITAS, CALIFORNIA -- August 22, 2023 -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage biotechnology company developing novel therapies for the treatment of ophthalmic diseases, today announced it has partnered with B2i Digital, Inc. to execute a comprehensive digital investor engagement and awareness program. B2i Digital will leverage its investor platform and digital marketing expertise to showcase Kiora's novel therapies for retinal diseases to retail and institutional investors. These digital efforts will be combined with traditional corporate access activities such as investor conferences, fireside chats, and Non-Deal Roadshows (NDRs).
"As we near a pivotal juncture in our clinical development pipeline, expanding access to the capital markets through innovative digital strategies is imperative," said Brian Strem, Ph.D., President & Chief Executive Officer of Kiora. "B2i Digital's leading-edge technologies will allow us to keep investors and strategic partners apprised of our progress and value proposition in a dynamic, timely manner."
"Kiora's novel therapies targeting orphan ophthalmic diseases piqued our interest from the outset," said David Shapiro, CEO of B2i Digital. "Once we examined their promising pipeline assets like KIO-301 and appreciated the potential to transform treatment for patients with retinal disease, we knew our digital investor engagement platform could significantly expand Kiora's investor base. We welcome them into our exclusive community of featured companies, telling their story to the thousands of daily b2idigital.com visitors, our 410,000+ social media community of sophisticated investors, and making individual introductions to key influencers in the capital markets."
"Our data-driven digital approach targets the most relevant investors,” added David Shapiro. “For Kiora, our platforms will generate broad awareness of their novel treatments for retinal diseases and showcase their immense potential in ophthalmology using our full suite of digital tools and platforms."